Revenue in Q3 2024 increased 20%, driven by volume growth from Mounjaro and Zepbound, partially offset by $1.42 billion of revenue in Q3 2023 from the sale of rights for the olanzapine portfolio ...
The agency has approved a four-dose version of the drug, called Mounjaro KwikPen, which provides a month’s course of GLP-1 and GIP agonist tirzepatide. Great Britain will be the first major ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback